Ensign Peak Advisors, Inc Alnylam Pharmaceuticals, Inc. Transaction History

Ensign Peak Advisors, Inc

$56.1 Billion
Q3 2024

A detailed history of Ensign Peak Advisors, Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 80,568 shares of ALNY stock, worth $19.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

80,568

Previous 73,473 9.66%

Holding current value

$19.6 Million

Previous $17.9 Million 24.14%

% of portfolio

0.04%

Previous 0.03%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $1.66 Million - $2.04 Million	7,095 Added 9.66%	80,568 $22.2 Million
Q2 2024 Aug 13, 2024	SELL	$143.31 - $247.0 $1.19 Million - $2.05 Million	-8,297 Reduced 10.15%	73,473 $17.9 Million
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $853,713 - $1.15 Million	-5,827 Reduced 6.65%	81,770 $12.2 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $4.3 Million - $5.58 Million	28,373 Added 47.91%	87,597 $16.8 Million
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $2.03 Million - $2.52 Million	11,904 Added 25.16%	59,224 $10.5 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $1.43 Million - $1.64 Million	7,745 Added 19.57%	47,320 $8.99 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $453,362 - $584,585	2,482 Added 6.69%	39,575 $7.93 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $289,983 - $377,167	1,563 Added 4.4%	37,093 $8.82 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $184,950 - $309,720	-1,335 Reduced 3.62%	35,530 $7.11 Million
Q2 2022 Aug 12, 2022	BUY	$120.42 - $169.29 $52,382 - $73,641	435 Added 1.19%	36,865 $5.38 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $550,689 - $753,030	-4,330 Reduced 10.62%	36,430 $5.95 Million
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $20.4 Million - $26.8 Million	-127,839 Reduced 75.82%	40,760 $6.91 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $703,444 - $860,833	-4,144 Reduced 2.4%	168,599 $31.8 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $635,689 - $874,190	4,942 Added 2.95%	172,743 $29.3 Million
Q1 2021 May 12, 2021	BUY	$126.83 - $175.69 $7.29 Million - $10.1 Million	57,463 Added 52.08%	167,801 $23.7 Million
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $352,923 - $421,890	-2,870 Reduced 2.54%	110,338 $14.3 Million
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $4.51 Million - $6.16 Million	37,241 Added 49.02%	113,208 $16.5 Million
Q2 2020 Aug 12, 2020	BUY	$104.21 - $156.44 $3.75 Million - $5.63 Million	36,010 Added 90.12%	75,967 $11.3 Million
Q1 2020 May 11, 2020	BUY	$93.12 - $133.99 $3.28 Million - $4.73 Million	35,266 Added 751.78%	39,957 $4.35 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $349,526 - $582,762	4,691 New	4,691 $540,000

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Alnylam Pharmaceuticals, Inc. Transaction History